A New Turn in Peptide-Based Imaging Agents: Foldamers Afford Improved Theranostics Targeting Cholecystokinin‑2 Receptor-Positive Cancer

Proteins adopt unique folded secondary and tertiary structures that are responsible for their remarkable biological properties. This structural complexity is key in designing efficacious peptides that can mimic the three-dimensional structure needed for biological function. In this study, we employ...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2021-04, Vol.64 (8), p.4841-4856
Hauptverfasser: Corlett, Alicia, Sani, Marc-Antoine, Van Zuylekom, Jessica, Ang, Ching-Seng, von Guggenberg, Elisabeth, Cullinane, Carleen, Blyth, Benjamin, Hicks, Rodney J, Roselt, Peter D, Thompson, Philip E, Hutton, Craig A, Haskali, Mohammad B
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Proteins adopt unique folded secondary and tertiary structures that are responsible for their remarkable biological properties. This structural complexity is key in designing efficacious peptides that can mimic the three-dimensional structure needed for biological function. In this study, we employ different chemical strategies to induce and stabilize a β-hairpin fold of peptides targeting cholecystokinin-2 receptors for theranostic application (combination of a targeted therapeutic and a diagnostic companion). The newly developed peptides exhibited enhanced folding capacity as demonstrated by circular dichroism (CD) spectroscopy, ion-mobility spectrometry–mass spectrometry, and two-dimensional (2D) NMR experiments. Enhanced folding characteristics of the peptides led to increased biological potency, affording four optimal Ga-68 labeled radiotracers ([68Ga]­Ga-4b, [68Ga]­Ga-11b–13b) targeting CCK-2R. In particular, [68Ga]­Ga-12b and [68Ga]­Ga-13b presented improved metabolic stability, enhanced cell internalization, and up to 6 fold increase in tumor uptake. These peptides hold great promise as next-generation theranostic radiopharmaceuticals.
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.0c02213